Detalles de la búsqueda
1.
A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.
Am J Hematol
; 89(5): 536-41, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24481640
2.
A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03).
Int J Radiat Oncol Biol Phys
; 103(5): 1158-1166, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30553941
3.
A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.
Leuk Lymphoma
; 60(4): 904-911, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30547695
4.
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group.
Leuk Lymphoma
; 52(5): 786-95, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21314490
5.
Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma.
Leuk Lymphoma
; 51(4): 641-9, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20218809
6.
The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement.
Eur J Haematol
; 76(6): 473-80, 2006 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-16529599
Resultados
1 -
6
de 6
1
Próxima >
>>